Navigation Links
Atherotech Says Detailed Cholesterol Test Can Help Doctors and Patients Choose Best Therapy
Date:1/31/2008

VAP Cholesterol test can help doctors and clinicians identify best

treatment options for patients at risk of heart disease

BIRMINGHAM, Ala., Jan. 31 /PRNewswire/ -- Clinical trial results from a new cholesterol-fighting drug combination point to the need for more detailed cholesterol testing, including direct measurement of LDL and other lipids. That's according to Atherotech, a cardio-diagnostic company that has developed an expanded cholesterol test called the VAP (Vertical Auto Profile) test, which can help doctors and clinicians identify the best treatment options for patients at risk of heart disease.

According to Atherotech Chief Medical Officer James Ehrlich, M.D., media reports about recently released trials have now resulted in widespread concern and confusion about the general value of lipid lowering agents, particularly statins, which play a critically important role in very high risk patients. Ehrlich pointed to a recent BusinessWeek article that raised multiple questions about the role of statins in the prevention of coronary disease, the nation's top killer.

"Atherotech believes that precise physician decisions about lifelong management of hypercholesterolemia can only be accomplished with a detailed profiling of lipoprotein components," said Atherotech Chief Medical Officer James Ehrlich, M.D. "By identifying the patient's true risk and by detailing his/her lipid profile with a VAP test, the physician can now successfully modify risk and improve the lipid levels in a rational manner. Some patients need combination therapy while others are well treated with monotherapy (statins)."

Ehrlich explained that new drugs and therapies are still important tools in helping individuals at risk to reach LDL goals, sometimes without statin therapy. However, he emphasized how we modify lipoprotein patterns may be more important in decreasing the risk of heart attack and stroke than simply lowering LDL cholesterol alone.

Unlike standard cholesterol tests that only measure LDL (bad cholesterol), HDL (good cholesterol), and total cholesterol, Atherotech's VAP test (http://www.thevaptest.com) enables direct, accurate measurement of important lipid subclasses and how they are transported and behave in the blood stream.

People who are already taking cholesterol lowering medication -- or have a family history or an existing condition of diabetes, high blood pressure or heart disease -- are candidates for the comprehensive VAP test, which directly measures fifteen separate components of blood cholesterol, including the identification of risk from lipid subclasses such as Lp(a), low HDL2 and small, dense LDL particles. These detailed measurements then allow the physician or clinician to determine the best therapy for reducing a patient's risk of heart attack and stroke.

The VAP Test is available nationwide.

About Atherotech, Inc.

Atherotech is a cardio-diagnostic company focusing on direct measurement of the comprehensive lipid panel using the company's VAP Technology. Specifically, VAP is a patented density gradient ultracentrifugation that directly measures the cholesterol content of all lipids, components and subclasses. The VAP test is the first cholesterol profile to comply with updated National Cholesterol Education Program ATP III recommendations calling for more accurate, direct low-density lipoprotein (LDL) measurement which is unaffected by triglycerides. Included in Forbes.com's list of "15 ways to Live Longer" and named one of "Five Tests Worth Paying For" by the Wall Street Journal, The VAP Cholesterol Test -- the new standard of care for patients at risk for cardiovascular disease -- is available through national and regional diagnostic laboratories and is reimbursed by most payers as well as Medicare. For more information, visit http://www.thevaptest.com.


'/>"/>
SOURCE Atherotech, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Phosphagenics Reports Superior Pre-clinical Cholesterol Results from APA-01 and Atorvastatin Combination
2. Phase 1 Studies Show Promise of QuatRxs Novel Compound, Sobetirome, for Lowering LDL Cholesterol Levels
3. Reverse Cholesterol Transport by RVX-208 a Small Molecule for ApoA-I Production Increase Presented at American Heart Association Scientific Meeting
4. New Survey Reveals Many Adults With High Cholesterol Fail to Take Necessary Steps to Improve Their Condition
5. Difficult to Treat Erectile Dysfunction Patients
6. TAP Pharmaceutical Products Inc. Files New Drug Application for TAK-390MR in Patients with Acid-Related Disorders
7. FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients
8. Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkins Lymphoma
9. Avastin Approved in Europe for First-Line Treatment of Patients With Advanced Kidney Cancer
10. A Must Read for Breast Cancer Patients
11. Survey of More than 600 Patients Treated with Tracleer(R) (bosentan) Reveals Actelion Sure Steps(R) Patient Support Program Provides Valuable Educational Information
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/12/2017)... ... , ... Each year, Crain’s Detroit Business News ranks the most innovative companies ... estate of a company, its impact and significance, and the likelihood of bringing it ... technologies that transform energy sources such as low dose X-ray and convert them into ...
(Date:1/12/2017)... ... January 12, 2017 , ... Huffman Engineering, Inc. , ... who will work in the company’s Lincoln office as a chemical engineer. In ... control systems for customers in the life science manufacturing and water/wastewater industries. , Prior ...
(Date:1/12/2017)... DC , January 12, 2017 ... up the world,s biggest facility for producing mycorrhizae. The ... the nutrient tapping potential of mycorrhizae and developed a ... ... (Logo: http://mma.prnewswire.com/media/456932/PRNE_TERI_Logo.jpg) The TERI facility ...
(Date:1/12/2017)... Pune, India , January 12, 2017 A new report ... and End Users - Global Opportunity Analysis and Industry Forecast, 2014-2022," projects that the ... million in 2015, growing at a CAGR of 15.07% during the forecast period. ... ... Research Logo ...
Breaking Biology Technology:
(Date:12/15/2016)... and BADEN-BADEN, Germany , December 15, 2016 ... financial services provider, today announced an agreement with NuData Security, ... to join forces. The partnership will enable clients to focus ... compliance with local data protection regulation. ... In order to provide a ...
(Date:12/15/2016)... , Dec. 14, 2016 "Increase in mobile ... market" The mobile biometrics market is expected to grow ... billion by 2022, at a CAGR of 29.3% between ... such as the growing demand for smart devices, government ... "Software component is expected to grow at ...
(Date:12/7/2016)... , December 7, 2016 BioCatch , the ... of its patent portfolio, which grew to over 40 granted and pending ... , , ... filed patent entitled " System, Device, and Method Estimating Force ... enables device makers to forego costly hardware components needed to estimate the ...
Breaking Biology News(10 mins):